Lilly Challenges US FDA Classification Of Obesity Drug Retatrutide, Citing Chevron Overturn

Determining what falls within the statutory definition of ‘biological product’ is an interpretative question that courts, rather than the agency, must resolve, Lilly said in a lawsuit repeatedly citing the US Supreme Court’s June decision in Loper Bright.